TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01855880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbGn-168H

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02174185

Intervention type: BEHAVIORAL
Intervention: validated health-related quality of life questionnaires
Description: All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.

Intervention type: BEHAVIORAL
Intervention: validated health-related quality of life questionnaires
Description: All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
Study: NCT04085861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy in dancers
Description: Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental health literacy in dance teachers
Description: Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
Study: NCT01127087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxazyme
Description: Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxazyme
Description: Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily.
Study: NCT00580229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone 40mg by mouth 30-60 minutes prior to rituximab
Study: NCT02498743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Animated cartoons
Study: NCT04640987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy System
Description: Device used for production of T-allo10 cells.
Study: NCT00673634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoxygenation
Description: Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP assisted preoxygenation
Description: Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
Study: NCT02838225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Doxorubicin, Cyclophosphamide
Study: NCT02826564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study: NCT03587987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopff
Description: manual ventilation
Study: NCT02427919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Comparison of the effect of G-CSF use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Comparison of the effect of G-CSF use
Study: NCT02940613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual feedback of symptom frequency
Description: Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
Study: NCT03587987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPap
Description: Manual ventilation
Study: NCT00219141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150/300 mg
Description: Aliskiren 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150/300 mg
Description: Aliskiren 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50/100 mg
Description: Losartan 50 or 100 mg capsules
Study: NCT02924025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
Study: NCT03578497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist Anakinra
Description: IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
Study: NCT04372641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: p97 Inhibitor CB-5339 Tosylate
Description: Given PO
Study: NCT00219141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50/100 mg
Description: Losartan 50 or 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren placebo
Description: Aliskiren 150 mg placebo tablet
Study: NCT04403620

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated Radiation Therapy (IMRT)
Description: Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated Radiation Therapy (IMRT)
Description: Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
Study: NCT04080076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar 80 UNT/ML Injectable Solution
Description: ACTHar 80 Units SQ 1042 x Week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tab Tacrolimus
Description: Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Tab Tacrolimus
Description: Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
Study: NCT00914303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3241
Description: Oral Tablet, Repeated Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Oral Tablet. Repeated Administration
Study: NCT00755911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tissue Repair Cells (TRC)
Description: 30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
Study: NCT04640987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy System
Description: Device used for production of T-allo10 cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy System
Description: Device used for production of T-allo10 cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-allo10 cells addback
Description: T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-allo10 cells addback
Description: T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-allo10 cells addback
Description: T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
Study: NCT03612895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal Care Coordination
Description: This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Community Referral
Description: Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
Study: NCT00219141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren placebo
Description: Aliskiren 150 mg placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren placebo
Description: Aliskiren 150 mg placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50/100 mg placebo
Description: Losartan 50/100 mg placebo capsules
Study: NCT02053779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1mg
Description: Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
Study: NCT03055832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLux 2020 System
Description: Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow Pulsation System
Description: Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
Study: NCT02724787

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Manage Emotions to Reduce Aggression (MERA)
Description: MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
Study: NCT03093844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi CliniMACS® CD34 Reagent System
Description: Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
Study: NCT05307900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confirmation of feeding tube placement in critically ill patients
Description: Confirmation of feeding tube placement using ultrasonography
Study: NCT01585922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noninvasive positive pressure ventilation (NPPV)
Description: Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: invasive mechanical ventilation
Description: Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
Study: NCT03108287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAK therapy
Description: rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBAK therapy
Description: rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
Study: NCT00988962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral training
Description: electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
Study: NCT00755911

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
Study: NCT01980979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remodulin
Description: Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
Study: NCT03508128

Intervention type: OTHER
Intervention: surgical procedure
Description: Surgical procedure
Study: NCT00755911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
Study: NCT04132375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INM004
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INM004
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INM004
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Study: NCT00453960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genivis
Description: 54 mg/day daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone Acetate
Description: tablets 10mg/day from day 16 to 25 of menstruation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets daily for 6 months
Study: NCT03190642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
Study: NCT00973349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
Study: NCT02609997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation
Description: The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation
Description: The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscoelastic materials
Description: viscoelastic materials are used to protect corneal endothelial cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscoelastic materials
Description: viscoelastic materials are used to protect corneal endothelial cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proparacaine
Description: 0.5% proparacaine (Alcaine, Alcon Laboratories)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proparacaine
Description: 0.5% proparacaine (Alcaine, Alcon Laboratories)
Study: NCT01677390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-75
Description: 1-2 mg/kg IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 10 mg PO daily
Study: NCT00812695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Gold standard treatment for Obstructive sleep apnea
Study: NCT00667446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3 Month Depot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3 Month Depot
Study: NCT00322153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine ER
Description: 28mg(7mg capsules) once daily and oral administration for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral administration once daily.
Study: NCT01879540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aTIV
Description: Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
Study: NCT03277833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)
Description: Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, parallel design
Study: NCT02951676

Intervention type: PROCEDURE
Intervention: Extraction
Description: Extraction of impacted third molar teeth

Intervention type: PROCEDURE
Intervention: Extraction
Description: Extraction of impacted third molar teeth
Study: NCT00769665

Intervention type: OTHER
Intervention: Systane Ultra
Description: Re-wetting ocular eye drop

Intervention type: OTHER
Intervention: Sensitive Eyes Rewetting Drops
Description: Re-wetting ocular eye drop
Study: NCT01165567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarpogrelate
Description: sarpogrelate, 300mg/day,duration: 4 weeks